Valeritas (NSDQ:VLRX) said today that it signed an exclusive distribution deal with Med Trust to commercialize its V-Go insulin delivery device in Austria and Germany. According to the terms of the agreement, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing. Med Trust will take over the sales, marketing and distribution activities […]
Valeritas (NSDQ:VLRX) touted data today from two new studies of its V-Go wearable insulin delivery device in patients with Type II diabetes. In one three-month evaluation of 60 people with Type II diabetes, researchers assessed if using V-Go could improve glycemic control in patients who were uncontrolled on prior treatment regimens. Get the full story at […]
Valeritas (NSDQ:VLRX) today announced a new $24m offering. In the offering, the Bridgewater, N.J.-based company will look to float approximately 13.7 million shares of common stock at $1.75 per share. The offering will also include a 30-day underwriter’s option for an additional 2.1 million shares at the same price. Read the whole story on our sister […]
According to a newly-inked deal between the two companies, Glooko plans to provide its diabetes data management platform to Valeritas (NSDQ:VLRX) for use with the medtech company’s next-gen V-Go insulin delivery device. Valeritas’ V-GO SIM device is an investigational accessory that the company said will snap onto its existing insulin delivery devices. The product is designed […]
Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with AMSL Diabetes and NZMS Diabetes for the commercialization of its V-Go wearable insulin delivery device in Australia and New Zealand. According to the terms of the agreement, AMSL Diabetes and NZMS Diabetes retain the right to promote, market and sell the V-Go device to clinics and […]
There are millions of Americans with Type II diabetes and many of them take multiple daily injections of insulin, using two injection pens – one for mealtime insulin and one for insulin throughout the day. But studies have found that people with Type II diabetes are willing to skip insulin injections if they have to […]
Valeritas (NSDQ:VLRX) has inked an exclusive distribution deal with Movi SpA for the commercialization of its V-Go wearable insulin delivery device in Italy. According to the terms of the deal, Movi will market and sell the V-Go device to diabetes clinics and patients in Italy, while Valeritas will remain responsible for the product’s development, regulatory approval […]
Valeritas (NSDQ:VLRX) said today that its V-Go wearable insulin delivery system is available in Puerto Rico. The Bridgewater, N.J.-based company has partnered with Fusion Consulting group to promote V-Go to Puerto Rico-based endocrinologists and general practitioners with Type II diabetes patients. Get the full story at our sister site, Drug Delivery Business News.
Valeritas (NSDQ:VLRX) touted positive findings today from an analysis of its V-Go wearable insulin delivery system with a weekly physician-driven insulin titration algorithm. Two-thirds of patients met their glycemic targets, the company said, and patient-reported hypoglycemia dropped by the end of the study. Get the full story at our sister site, Drug Delivery Business News.
Valeritas (NSDQ:VLRX) said today that it inked a deal with Aspire Capital Fund to buy $20 million of Valeritas’ common stock. According to the deal, Aspire Capital is slated to purchase common stock at Valeritas’ request from time to time during a 30-month period at prices based on the market price at the time of each […]
In a retrospective analysis of 86 diabetic patients who switched from multiple daily insulin injections to the V-Go insulin pump, Valeritas (NSDQ:VLRX) reported this week that use of its device led to a 44% reduction in total daily insulin dose per patient. A drastic cut to a patient’s daily insulin dose and improvement to their blood sugar levels […]